Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

Published:2017-04-20 Issue:7 Volume:20 Page:692-702
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Saint-Laurent Thibault Catherine¹^ORCID,Moorjaney Divya²,Ganz Michael L.³^ORCID,Sill Bruce⁴,Hede Shalini⁵,Yuan Yong⁵,Gorsh Boris⁶

Affiliation:

1. Evidera, Montreal, QC, Canada;

2. QuickPivot, Boston, MA, USA;

3. Evidera, Waltham, MA, USA;

4. Bristol-Myers Squibb, Hartford, CT, USA;

5. Bristol-Myers Squibb, Plainsboro, NJ, USA;

6. GlaxoSmithKline, Upper Providence, PA, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1307204

Reference49 articles.

1. The global burden of hepatitis C

2. Global epidemiology of hepatitis C virus infection

3. US Centers for Disease Control (CDC). Hepatitis C FAQs for health professionals, 2016. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed January 10, 2016

4. US Centers for Disease Control (CDC). Viral hepatitis surveillance, United States, 2013. http://www.cdc.gov/hepatitis/statistics/2013surveillance/pdfs/2013hepsurveillancerpt.pdf. Accessed January 19, 2016

5. Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C;Hepatitis Monthly;2021-11-13

2. Molecular docking and statistical optimization of taurocholate-stabilized galactose anchored bilosomes for the enhancement of sofosbuvir absorption and hepatic relative targeting efficiency;Drug Delivery;2020-01-01

3. 12 W eeks of a R ibavirin‐ F ree S ofosbuvir and N onstructural P rotein 5 A I nhibitor R egimen I s E nough to T reat R ecurrence of H epatitis C A fter L iver T ransplantation;Hepatology;2018-10

4. A Guide to the Economics of Hepatitis C Virus Cure in 2017;Infectious Disease Clinics of North America;2018-06

5. Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence;MDM Policy & Practice;2018-01